The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksBatm Advanced Regulatory News (BVC)

Share Price Information for Batm Advanced (BVC)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 19.65
Bid: 18.40
Ask: 19.65
Change: 0.00 (0.00%)
Spread: 1.25 (6.793%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 19.65
BVC Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Delivery of First Insect Protein Recovery Facility

7 Dec 2020 07:00

RNS Number : 6762H
BATM Advanced Communications Ld
07 December 2020
 

LEI: 213800FLQUB9J289RU66

7 December 2020

 

BATM Advanced Communications Limited

("BATM" or "the Group")

 

BATM Delivers First Insect Protein Recovery Facility

New ISS-based instrument to produce high-quality insect protein powder and oil

 

BATM (LSE: BVC; TASE: BVC), a leading provider of real-time technologies for networking solutions and medical laboratory systems, is pleased to announce that Celitron, the Group's subsidiary that is part of the Eco-Med unit, has completed the delivery of the first of its new instrument that recovers high-quality protein and oils from insects to a world renowned company focused on commercialising industrial scale insect-based technologies to produce feedstock. The entry into a new market segment with the first delivery of this instrument marks a further milestone achieved by Celitron in 2020.

 

The Group's new instrument provides a continuous and automated process for the recovery of solid protein and oils from insects such as worms and flies that feed on waste. It is based on Celitron's innovative Integrated Sterilizer and Shredder ("ISS") technology that is designed for sterilising harmful agricultural and medical waste and rendering them benign. The ISS also has the advantage of enabling a streamlined process and being far more cost-effective compared with any competing solutions.

 

The customer, which is headquartered in Belgium, recycles insect nutrients into valuable products for the feedstock industry. The customer intends to use the Group's solution to produce insect protein powder that can be used as a substitute for fishmeal and oils that can be used in aquaculture feed. The Group expects to receive orders from this customer for further instruments in due course.

 

This contract is in addition to other contracts for the Group's ISS-based solutions delivered in 2020 in Europe and Asia, with the Group having received orders of $8.3m for this technology in 2019 and 2020. With demand for protein on the rise and the crucial need to ensure protein safety along with an increased interest in the ISS, the Group is confident of adding to this total in 2021.

 

A video showing the instrument in operation at the customer's facility can be accessed here: https://youtu.be/4Pat7itiUQ8 

 

Dr Zvi Marom, Chief Executive Officer of BATM, said: "I am delighted that we have delivered the first of this new protein recovery instrument and I congratulate the Celitron team for achieving this major milestone despite the logistical challenges of the COVID-19 pandemic. After several years of development at our facility in Hungary, we have now established a best-in-class solution based on our superior ISS technology. The production of protein and oil from animal waste, and, in particular, from the rearing of insects, has enormous potential as a sustainable source of protein for fishmeal, livestock feed and potentially even human nutrition.

 

"All of BATM's units are going from strength to strength not only in their financial performance, but also in introducing innovative technology that we believe will be of benefit to society for many years to come. I take great pride in these achievements and look forward to reporting our progress."

 

 

Enquiries:

 

BATM Advanced Communications

 

Dr Zvi Marom, Chief Executive Officer

+972 9866 2525

Moti Nagar, Chief Financial Officer

 

 

 

 

 

Shore Capital

 

Mark Percy, Anita Ghanekar, James Thomas (Corporate Advisory)

Henry Willcocks (Corporate Broking)

+44 20 7408 4050 

 

 

 

 

Luther Pendragon

 

Harry Chathli, Claire Norbury

+44 20 7618 9100

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCUPGRWPUPUGCQ
Date   Source Headline
14th Apr 20229:30 amRNSAnnual Financial Report
13th Apr 20227:00 amRNSAppointment of Non-Executive Director
4th Apr 20227:00 amRNSTransaction in Own Shares and TVR
18th Mar 20227:00 amRNSStrategic Partnership for Edgility with NEXCOM
17th Mar 202210:30 amRNSResult of General Meeting
10th Mar 202212:30 pmRNSHolding(s) in Company
8th Mar 202211:30 amRNSHolding(s) in Company
28th Feb 20227:00 amRNSFull Year Results
23rd Feb 20227:00 amRNSNotice of General Meeting
21st Feb 20227:00 amRNSStrategic Partnership for Edgility with Advantech
17th Feb 20227:00 amRNSTrading Update and Notice of Results
3rd Feb 202211:23 amRNSClarification on FTSE Nationality Review
3rd Feb 20227:00 amRNSUpdate on FTSE Nationality Review & Share Buyback
31st Jan 20227:00 amRNSUpdate on Ador Diagnostics
17th Jan 20227:00 amRNSUpdate on FTSE Nationality Review
4th Jan 20227:00 amRNSDividend Declaration
4th Jan 20227:00 amRNSTotal Voting Rights
16th Dec 20217:00 amRNSFirst sales of rapid COVID-19 test in Russia
14th Dec 202111:45 amRNSResult of AGM and Dividend Declaration
30th Nov 20217:00 amRNSCOVID-19 tests effective in diagnosing Omicron
25th Nov 20213:00 pmRNSBlock Listing Interim Review
22nd Nov 20213:00 pmRNSNotice of AGM and Dividend Declaration
10th Nov 20217:00 amRNSBATM receives $3.5m cyber security contract
3rd Nov 20217:00 amRNSNew five-year contract for Edgility
1st Nov 20217:00 amRNSBATM receives agri-waste contract in Botswana
7th Oct 20217:00 amRNSStrategic partnership for NFV with AudioCodes
13th Sep 20217:00 amRNSFirst enterprise customer for NFV with $2m order
23rd Aug 20217:00 amRNSInterim Results
12th Aug 20217:00 amRNSNotice of Results
12th Jul 20217:00 amRNSLaunch of Edgility networking NFV-based ecosystem
5th Jul 20217:00 amRNSBATM receives $10m cyber security contract
15th Jun 20217:00 amRNSBATM receives $4.1m cyber security contract
26th May 20217:00 amRNSBlock listing Interim Review
18th May 20217:00 amRNSBATM commences delivery of new COVID-19 tests
19th Apr 202110:25 amRNSAnnual Financial Report
12th Apr 20217:00 amRNSStrategic partnership for NFV
29th Mar 20217:00 amRNSBATM develops molecular diagnostics test for TB
19th Mar 20217:00 amRNSCompletion of Sale of NGSoft
11th Mar 20217:00 amRNSBATM launches no-swab saliva-based COVID-19 test
1st Mar 20217:00 amRNSUpdate on Sale of NGSoft
22nd Feb 20217:00 amRNSFull Year Results
11th Feb 20215:38 pmRNSFTSE Nationality Review
1st Feb 20217:00 amRNSTrading Update and Notice of Results
19th Jan 20217:00 amRNSBATM's NFVTime now available for the public cloud
12th Jan 20217:00 amRNSBATM enters option agreement to sell NGSoft
24th Dec 20207:00 amRNSCOVID-19 test effective in diagnosing new strain
17th Dec 20203:50 pmRNSResult of AGM
15th Dec 20207:00 amRNSUpdate on Ador Diagnostics
7th Dec 20207:00 amRNSDelivery of First Insect Protein Recovery Facility
30th Nov 20203:03 pmRNSTotal Voting Rights and Share Capital

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.